Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Clinical diagnosis of schizophrenia

• Ability to remain hospitalized for at least first 4 weeks of study

• Needs hospitalization due to worsening of schizophrenia

Exclusion Criteria:

• Type 1 or 2 diabetes

• Previous use of clozapine

• Serious medical illness other than schizophrenia